DBV DBV Technologies SA
Financings ·
DBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price.
DBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $5.6 million | $4.2 million |
| Research and development | $116.7 million | $89.3 million |
| Net income (loss) | -$146.9 million | -$113.9 million |
| Cash from operations | -$121.2 million | -$104.5 million |
| Cash and equivalents | $194.2 million | $32.5 million |
Our latest story on this, dated Sep 5, 2025: "DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq". The story links the filing or release it is based on. Read the story.
DBV Technologies SA trades under the ticker DBV on EURONEXT.
DBV Technologies SA is listed on EURONEXT. Our directory also records these other listings: DUS:DBV; FWB:DBV; GETTEX:DBV; HAM:DBV; HAN:DBV; LS:A1JWB7; LSIN:0QAJ; LSX:A1JWB7; MUN:DBV; NASDAQ:DBVT; SWB:DBV; TRADEGATE:DBV; XETR:DBV.
The SEC Central Index Key (CIK) for DBV Technologies SA is 1613780. Its filings are on SEC EDGAR.
296,061,497 shares as of 2026-07-16, per the cover page of its 10-Q filed 2026-07-16.
Our directory records DBV Technologies SA under France.
Our directory classifies DBV Technologies SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for DBV Technologies SA is FR0010417345.
aibio.space lists DBV Technologies SA among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as I0.
$5.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
DBV Technologies SA reported a net loss of $146.9 million for the fiscal year ended Dec 31, 2025, and used $121.2 million of cash in operations, per its annual report to the SEC.
$116.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$165.7 million in cash at Sep 30, 2026, per its 10-Q.
Our latest story on DBV Technologies SA, dated Sep 5, 2025: "DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq". DBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price. Source.
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio